New Zealand markets closed

Avenue Therapeutics, Inc. (ATXI)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1516-0.0029 (-1.88%)
At close: 04:00PM EST
0.1472 -0.00 (-2.90%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.1545
Open0.1520
Bid0.0000 x 1400
Ask0.0000 x 1200
Day's range0.1475 - 0.1570
52-week range0.1130 - 1.3600
Volume854,379
Avg. volume5,617,838
Market cap5.655M
Beta (5Y monthly)-0.28
PE ratio (TTM)N/A
EPS (TTM)-2.6200
Earnings date28 Mar 2024 - 01 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est16.38
  • GlobeNewswire

    Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

    -In vivo data supports BAER-101’s unique ability to significantly suppress seizures using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy-MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of preclinical in vivo data in

  • GlobeNewswire

    Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference

    MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer, will present a corporate update at the Sidoti January Micro-Cap Investor Conference on Thursday, January 18, 2024 at 10:00 a.m. EST. A webcast and subsequent archived replay of th

  • GlobeNewswire

    Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds

    MIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the entry into warrant exercise agreements with existing accredited investors for the immediate exercise of certain outstanding warrants to purchase an aggregate of 16.5 million shares of the Company’s common stock. These warrants for